Apr
14
What is BHRT and 5 ways it Could Benefit Your Patients
What is BHRT and 5 ways it Could Benefit Your Patients Written by Krista Russ Previously, we discussed how patients are taking more medications and experiencing an endless conundrum of health issues. The systemic failure to address the root causes of disease is a huge part of the problem. Along with the proven benefits of
DETAIL
Sep
27
How to Protect Against Collateral Damage
By Neal Rouzier, MD This is the last and final newsletter before the upcoming Hormones and Beyond 2021. I hope that you have enjoyed the commentary of these newsletters. They are an introduction as to what will be presented at Hormones and Beyond in 2 weeks. My primary focus on Friday will address reversal of
DETAIL
Sep
23
PCSK-9 Inhibitors : Another Therapeutic Illusion
By Neal Rouzier, MD Recently, a new cholesterol lowering drug was approved in the U.K. The press-release heralded Inclisiran, simply another PCSK-9 inhibitor, to be a game changer as it will save thousands of lives by lowering cholesterol. No, there are no outcome studies yet, only studies that demonstrate it lowers serum cholesterol 50% more
DETAIL
Aug
06
Treating T3 Deficiency: Recent Literature Supports That Low Free T3 was the Highest Independent Predictor of Death in CV Patients
Recommended Pre-Reading: Treating T3 Deficiency, The Evidence You Need Interested in monthly webinars? Upgrade your Membership SCENARIO: A 59 y/o female with CVD is referred by her friend for evaluation of hypothyroidism. Laboratory tests consistently show a mildly elevated TSH and normal Free T4. Despite multiple attempts to try to get her PMD to prescribe a trial
DETAIL
Jul
26
CVD: Could all the Medicines that we Prescribe, Including Statins, be Increasing the Risk of Cancer?
By Neal Rouzier, MD CVD is the # 1 killer in the U.S. and worldwide. The medical literature and pharmaceutical industry has led us to believe in the cholesterol-centric model in preventing CVD. Unfortunately, utilizing cholesterol-lowering medication has only led to a 1-3% absolute risk reduction (ARR) in CVD and mortality. Not very impressive for all
DETAIL
Jul
14
The CVD and Cancer Insanity Cycle : What Should we do if What we are Doing Isn’t Working?
By Neal Rouzier, MD As clinicians we try to be problem solvers. It is part of our training, try to figure out what’s wrong, and then to fix it. Problem solved. However, what should we do if what we are doing isn’t working? Keep doing the same thing? What if the patient does not get better?
DETAIL